Denali Therapeutics (DNLI) closed at $19.28 on Oct 6, 2026, down 3.2% on the day. The stock is down 13.5% over the past month, down 27.8% over three months, up 16.8% year to date and up 25.0% over the past year. It trades 29.4% below its 52-week high of $27.30 and 40.2% above its 52-week low of $13.75. The close sits below its 50-day moving average ($22.71) and below its 200-day moving average ($21.08).
No — the Oct 6, 2026 close of $19.28 is 8.6% below the 200-day average of $21.08.
DNLI closed 29.4% below its 52-week high of $27.30.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
